BioAge Labs wants to raise $200 million in IPO to develop obesity and diabetes drugs
Subtitles
  • Off
  • English

BioAge Labs wants to raise $200 million in IPO to develop obesity and diabetes drugs

The pharmaceutical company is developing weight loss drugs by targeting "the biology of human aging"
We may earn a commission from links on this page.

Advertisement

Advertisement